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ABSTRACT 
Introduction: Post-transplant lymphoproliferative disorder (PTLD) is a recognized complica-
tion exclusive to solid organ transplant recipients and carries a high mortality.  
Methods: We retrospectively reviewed records of all renal transplant recipients under follow 
up at our institution over the last seven years (2005-2011). We reviewed the patient character-
istics, immunosuppression regimen and risk factors for the development of PTLD and its out-
comes in our transplant cohort.  
Results: Four out of 63 patients were diagnosed with PTLD. PTLD was incidentally diag-
nosed on a transplant biopsy that was performed for an unexplained rise in serum creatinine in 
three patients. The fourth patient presented with left submandibular lymphadenopathy. Major-
ity presented within 18 months of renal transplantation. After the diagnosis of PTLD on graft 
biopsy, all patients were fully investigated and two patients had systemic involvement. In the 
patients with systemic involvement, reduction of immunosuppression and anti B cell therapy 
with Rituximab was used with good success. The patient with submandibular lymphadenopa-
thy received chemotherapy in addition to reduction of immunosuppression. Three PTLD cases 
were polyclonal and diagnosed early whereas the fourth case was monoclonal.  
Conclusion: PTLD can sometimes be incidentally diagnosed on an allograft biopsy per-
formed for rejection. The incidence of PTLD in our centre is higher than reports from other 
centres but our outcome is good if recognised and treated early.  
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INTRODUCTION 
Post-transplant lymphoproliferative dis-
order (PTLD) is a recognized complication 
exclusive to solid organ transplant recipi-
ents and is the second most common malig-
nancy after skin cancers in these patients 
(Ondrus et al., 1999). Malignancy is the 
leading cause of death after infections and 
cardiovascular disease in renal transplant 
recipients. The incidence of PTLD is about 
1 % in adult renal transplant recipients but 
has been reported to be higher in paediatric 
recipients (Dharnidharka et al., 2001). The 
incidence is lowest in renal transplant recip-
ients compared to heart, liver or lung trans-
plant recipients and can be as high as 6-
10 % in lung transplants recipients (Miha-
lov et al., 1996). The intensity and type of 
immunosuppression are associated with the 
development of PTLD (Dharnidharka et al., 
2001). Other risk factors include Epstein-
Barr virus (EBV) seronegative recipients 
(Cockfield et al., 1993; Manez et al., 1994), 
co-existing Cytomegalovirus (CMV) infec-
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tion (Manez et al.,1994; Walker et al. 
1995a), the use of monoclonal anti-CD3 
antibody and cadaveric transplant recipi-
ents. Despite treatment, PTLD carries 60 % 
mortality (Caillard, et al., 2006). Initial 
therapy in PTLD is immunosuppression 
reduction which can sometimes result in 
complete remission but carries the risk of 
rejection (Tsai et al., 2001). 
We noted an increase in the incidence 
of PTLD at our institution (Ciancio et al., 
1997). This prompted the review of patient 
characteristics, immunosuppression regi-
men and risk factors for the development of 
PTLD and its outcomes in our transplant 
cohort.  
 
PATIENTS AND METHODS 
We retrospectively reviewed records of 
all renal transplant recipients under follow 
up at our institution over the last 7 years 
(2005-2011) from our database and collect-
ed data on the patients diagnosed with 
PTLD after renal transplantation. We col-
lected the demographics of patients (age, 
gender and sex), type of renal transplant, 
the use and type of an induction agent, im-
munosuppressive regimen, renal function 
and age at diagnosis of PTLD.  We also 
collected data on primary diagnosis of 
ESRD, time to developing PTLD, type of 
donor kidney, donor and recipient CMV 
and EBV serology, episodes of rejection, 
episode of calcineurin inhibitor toxicity, 
treatment received and outcome.  
The diagnosis of PTLD was made based 
on histology and in most cases from a renal 
transplant biopsy specimen. The specimens 
were all reviewed by a consultant histo-
pathologist who verified the diagnosis of 
PTLD.  
 
RESULTS 
Four out of 63 patients were diagnosed 
with PTLD. Their demographics and char-
acteristics are tabulated on Table 1. PTLD 
was incidentally diagnosed on a transplant 
biopsy that was performed for an unex-
plained rise in serum creatinine in three pa-
tients. The fourth patient presented with 
symptoms of fever, upper respiratory tract 
infection and left submandibular lymphad-
enopathy and PTLD was diagnosed from 
lymph node biopsy. Once PTLD was diag-
nosed, patients were fully investigated and 
2 patients had systemic involvement. 
In most of the patients we did not have 
the donor details in terms of CMV and 
EBV serology, and type of induction agent 
(if used) as majority were done overseas 
with commercial donors. 
 
DISCUSSION 
PTLD occurred in 6 % of our transplant 
patients and was notably higher in our co-
hort than the 1 % reported rate (Gersten-
korn et al., 2001). Interestingly, the majori-
ty of our patients was asymptomatic. Three 
cases of PTLD were incidentally diagnosed 
on an allograft biopsy for an acute rise in 
serum creatinine. PTLD can occur within 
the allograft and should be considered as a 
differential diagnosis for acute rejection.  
The incidence of PTLD varies with the 
organ transplanted, the presence and inten-
sity of immunosuppression (especially Cy-
closporine A based regimens), EBV sero-
negative recipients, co-existing CMV infec-
tion and cadaveric transplant recipients 
(Cockfield et al., 1993; Manez et al., 1994; 
Walker et al., 1995a; Izadi et al., 2011; 
Sampaio et al., 2012) The use of 
Muromonab-CD3 (OKT3) as an induction 
agent has also been associated with the de-
velopment of PTLD (Cockfield et al., 1993; 
Walker et al., 1995a). We believe the pos-
sible reasons for our higher incidence of 
PTLD are EBV infection and a higher de-
gree of immunosuppression. Until recently, 
a third of all Malaysian renal transplants 
were commercial cadavers and therefore no 
data is available on the EBV status of the 
donor. In case 3, the patient had two previ-
ous episodes of rejection, hence the need 
for augmented immunosuppression. Several 
studies have shown a higher incidence of 
PTLD in paediatric renal transplant recipi-
ents as many paediatric patients are EBV 
naive compared to the adult population who 
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is predominantly EBV seropositive 
(Dharnidharka et al., 2001). Studies have 
demonstrated EBV seronegative pre-
transplantation increases the risk of primary 
infection with EBV and development of 
PTLD increases by 76 six fold (Walker et 
al., 1995b; Sampaio et al., 2012). 
 
 
Table 1: Demographics and characteristics of patients with PTLD 
 Patient 1 Patient 2 Patient 3 Patient 4 
Age (years) 38 39 49 55 
Gender Male Male Male Male 
Type of renal Tx Spousal Commercial  
cadaveric 
Commercial  
? Live unrelat-
ed 
? Cadaveric 
Commercial  
cadaveric 
Year of Tx 2007  2006  2005  2002 
Duration post Tx 
at PTLD diagno-
sis (months) 
13  16  39  118 
Induction agent Basiliximab Unknown Unknown Unknown 
Immunosuppres-
sion regime at 
diagnosis 
Prednisolone, 
Mycophenolate 
mofetil 
Sirolimus 
Prednisolone, 
Mycophenolate 
mofetil,  
Cyclosporin A 
Prednisolone, 
Mycophenolate  
mofetil, 
Cyclosporin A 
Prednisolone, 
Mycophenolate 
mofetil, 
Tacrolimus 
Episode of rejec-
tion before PTLD 
No  No  Two  No  
Episode of CNI 
toxicity 
Yes No  No  No  
EBV status D/R D+/R-  D unknown/R+ D unknown/R+ D unknown/R+ 
CMV status D/R D+/R+  D unknown/R-  D unknown/R+  D unknown/R+ 
Type of PTLD Polymorphic Polymorphic Polymorphic Monomorphic 
Site of PTLD Renal graft Renal graft Renal graft Submandibular 
lymph node 
Systemic in-
volvement 
No  Yes (lymph node) Yes  
(lymph node)  
Yes  
(lymph node)  
Treatment Reduction in  
immuno-
suppression  
Reduction in im-
munosuppres-
sion, Rituximab 
500 mg x 4 doses 
Reduction in 
immunosup-
pression, Ritu-
ximab 500 mg 
x 4 doses, IV 
immunoglobulin 
Reduction in im-
munosuppres-
sion, CHOP 
chemotherapy 
Outcome Alive, stable graft 
function  
Alive, stable graft 
function  
Developed fur-
ther episode of 
acute cellular 
rejection due to 
minimisation of 
immunosup-
pression.  
Died due to 
septicaemic 
shock from 
pneumonia 
Responded to 6 
cycles of chemo-
therapy. PET 
scan shows re-
mission. No epi-
sodes of rejection 
so far despite 
minimal immuno-
suppression 
Tx – Transplant; CMV – Cytomegalovirus; EBV – Epstein-Barr virus; PTLD- Post transplant lympho-
proliferative disorder; CNI – calcineurin inhibitor; D/R- Donor/Recipient 
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PTLD can be classified into a polyclo-
nal or monoclonal proliferation of B lym-
phocytes or T lymphocytes (Swerdlow 
1992; Anonymous, 2004). The majority of 
our PTLD cases was polyclonal and diag-
nosed early. PTLD starts off as polyclonal 
and then becomes monoclonal. Most 
PTLDs arise from B cell as EBV has a pre-
dilection for B cells.  
The majority of our patients presented 
within 18 months of transplantation which 
is in keeping with reported data. The risk of 
developing PTLD is highest in the first year 
after solid organ transplantation when im-
munosuppression is at its highest and is 
mostly driven by EBV infection. Studies 
have shown that recipients with late onset 
PTLD frequently presented with monomor-
phic lesions and a significantly higher risk 
of disseminated disease (Izadi et al., 2011). 
Our study found similar findings in that our 
first two cases presented early on with pol-
ymorphic PTLD. Patient 3 although pre-
sented late was polymorphic whereas pa-
tient 4 was monomorphic.  
Allograft involvement can occur in re-
nal transplant recipients with PTLD as evi-
denced by 3 of our cases with it being local-
ized to the graft only. Khedmat and Taheri 
(2010) demonstrated 37 % of their patients 
had PTLD confined to allograft and this 
subset of patients had better survival than 
other PTLD patients unless they developed 
multi-organ involvement. Five-year surviv-
al rate was 73 % for graft PTLD and 42 % 
for other localizations. Graft PTLD patients 
had shorter time from transplant to PTLD 
and were more likely to present as polyclo-
nal and polymorphic (Khedmat and Taheri, 
2010). Our findings concur with this. 
Treatment of PTLD involves a few reg-
imens – the mainstay of treatment is reduc-
tion of immunosuppression in all cases alt-
hough currently, there is no standardized 
approach (Tsai et al., 2001). European 
guidelines recommend stopping the antime-
tabolite and minimizing the calcineurin in-
hibitor by at least 50 %, some say about 
20 % every two weeks until about 30 % of 
the initial dose (European best practice 
guidelines, 2002). However, immunosup-
pression reduction is associated with a 
higher risk of graft rejection and graft loss 
with reported rejection rates of 37 % (Tsai 
et al., 2001). Reduction of immunosuppres-
sion allows the recovery of the recipients T 
cells which perform surveillance against 
EBV infected cells. However, response rate 
to immunosuppression reduction alone is 
low (Gerstenkorn et al., 2001). 
Another strategy is the treatment with 
antivirals in EBV driven PTLD. Estimation 
of EBV viral load allows pre-emptive 
prophylaxis by treatment with antiviral 
agent for at least one month and depending 
on viral load (European best practice guide-
lines, 2002). However, these agents will 
only inhibit the lytic phase and decrease the 
degree of shedding of virus but the number 
of EBV infected cells is not altered by acy-
clovir treatment. 
Other treatment strategies include 
Rituximab monotherapy in CD20-positive 
B-cell PTLD (Elstrom et al., 2006) or 
CHOP-like chemotherapy (Choquet et al., 
2007). Hematotoxicity, leading to infec-
tious complications and treatment-related 
mortality is the therapeutic limitation of 
CHOP. Renal graft function may be de-
creased at the time of diagnosis but signifi-
cantly improves following treatment of the 
lymphoma (Trappe et al., 2009). Compared 
with renal transplant controls with stable 
graft function, PTLD patients receiving 
chemotherapy had a non inferior graft func-
tion at follow-up (Trappe et al., 2009). This 
suggests that the negative impact of immu-
nosuppression reduction on graft function 
can be compensated by the immunosup-
pressive effect of CHOP, suppressing both 
cell-mediated and humoral immunity 
through its effects on T and B cells 
(Gholipour-Shoiili et al., 2011). Converse-
ly, patients with PTLD may be over immu-
nosuppressed. Overall reported response 
rates are about 40–60 % for single agent 
Rituximab and up to 90 % for sequential 
treatment with four courses of Rituximab 
followed by four cycles of CHOP (Trappe 
et al., 2009). Anti-CD20 monotherapy is 
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therefore the preferred treatment modality 
in PTLD when patients fail to respond to 
upfront immunosuppression reduction, alt-
hough they seem to be less effective in 
high-risk patients. 
In our cohort, patients with systemic in-
volvement received Rituximab with good 
response rates. In the case of patient 3 (who 
was also diabetic), he had been treated 
twice for rejection previously and therefore 
received higher level of immunosuppres-
sion. After the diagnosis of PTLD, we re-
duced his immunosuppression and treated 
him with Rituximab. About 18 months lat-
er, he developed another episode of cellular 
rejection for which he received high dose 
steroids, but developed recurrent septicae-
mia episodes and eventually succumbed to 
it. 
Nephrectomy has been suggested for 
PTLD in renal allograft. Studies demon-
strate that survival analysis in patients with 
renal allograft involvement who underwent 
allograft nephrectomy had a significantly 
better outcome compared to non nephrec-
tomised patients (Gholipour-Shoiili et al., 
2011). In patients with disseminated PTLD, 
nephrectomy was not useful and some 
would consider this a drastic measure, as 
life on dialysis carries a significant psycho-
social burden.(Gholipour-Shoiili et al., 
2011). 
Mortality has been reported to be over 
50 % (Caillard et al., 2006). Meta-analysis 
in liver transplant recipients have reported 
one and five years survival rate for early 
onset PTLD to be 64 % and 54 % respec-
tively (Izadi and Taheri, 2011). 
 
CONCLUSION 
PTLD can sometimes be incidentally 
diagnosed on an allograft biopsy that was 
performed for rejection. Therefore renal 
transplant recipients who develop allograft 
dysfunction during the early post-trans-
plantation period should be investigated for 
potential PTLD development at their allo-
graft site. The outcome is good if recog-
nized and treated early.  
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